I nterleukin-15 is a cytokine that has effects on cells of the innate and adaptive immune system. It is most known for its effects in promoting the survival, differentiation, and activation of NK cells, as well as promoting memory CD8 T cell responses (1) (2) (3) . Because both NK cells and CD8 T cells are important in tumor defense and correlate with survival in various cancers, there has been extensive interest in IL-15 as an immunotherapy (4) (5) (6) . The effects of IL-15 have been assessed in many tumor models, and it has been found to be effective against primary tumors as well as metastasis (7) (8) (9) . In many cases, the mechanism of protection from metastasis was not evaluated. When investigated in models of metastasis, NK cells were most frequently the cell type identified that was important for protection (7, 9) .
In recent years, it has become apparent that macrophages are very important cell types involved in the promotion of metastasis. Classically activated macrophages, also known as M1, are able to promote tumor cell death due to their production of NO, proinflammatory cytokines, efficient Ag presentation, and phagocytic abilities (10, 11) . In contrast, the alternatively activated group of macrophages (M2), of which tumor-associated macrophages (TAMs) are a member, has more of a role in tumor promotion (10, 12) . It functions to promote angiogenesis, tumor cell invasion, and intravasation, and it plays a role at the metastatic site (11) . Macrophages are very plastic and are able to travel between M1 and M2 states depending on the microenvironment in which they are found (13) . M1 macrophages are created in environments with stimuli such as IFN-g and LPS (14) . M2 is a group of macrophages that can develop under the influence of IL-4/IL-13, immune complexes, IL-10, TGF-b, or glucocorticoids (14) . Although the role of macrophages at the primary tumor is well established, a lot less attention has been paid to the role of macrophages at the metastatic site. Kaplan et al. (15) found that after primary tumors have been established, but before metastasis has occurred, there are premetastatic sites in which there are clusters of vascular endothelial growth factor receptor + hematopoietic bone marrow progenitors. CD11b + myeloid cells are also attracted to these premetastatic niches, and these cells are important for establishing metastasis (16) . Recently, to investigate the role of macrophages at the metastatic site, several groups have used the injection of tumor cells i.v. to mimic tumor metastasis. In models such as this, macrophages are required for efficient tumor cell seeding as well as growth at the metastatic site (17, 18) .
Macrophage polarization is dependent upon the signals it receives in its microenvironment. It is, of course, no wonder that CD4 T cells play a role in macrophage polarization. Th1 CD4 T cells produce IFN-g, which promotes M1 macrophage polarization, whereas Th2 or regulatory T cells produce IL-10, IL-4, or IL-13, which promotes M2 macrophage polarization (19) . In fact, in mouse models that are Th2 biased, knockout of CD4 T cells promotes the formation of macrophages with a more M1 phenotype (20, 21) . Macrophages also influence the polarization of T cells themselves, with M2 macrophages promoting the formation of T regulatory cells (22) . Recently, it was discovered that, in a spontaneous model of breast tumor formation, CD4 T cells expressing IL-4 were able to promote invasion and metastasis due to their effects on promoting M2 phenotype in TAMs (20) . In this case, loss of CD4 T cells actually decreased the amount of metastasis observed (20) . Other studies have also indicated that CD4 T cells may play a role in promoting metastasis, although via different mechanisms (23, 24) .
The effect of IL-15 on macrophages and CD4 T cells is an area that has not been studied thoroughly. It is known that IL-15 is produced from human monocytes upon LPS activation (25) . Several in vitro studies on various sources of macrophages (mouse peritoneal macrophages, RAW cells, human monocytes) indicate that IL-15 is able to stimulate proinflammatory cytokine release (TNF-a, IL-1, IL-6, IL-8, MCP-1) as well as NO production (26, 27) . Others have also determined that IL-15 treatment promotes the formation of macrophages with higher costimulatory molecules (CD80/86) as well as increased MHCII (28) . The reported effects of IL-15 on CD4 T cells are rather contradictory. Early reports indicated IL-15 could prime CD4 T cells for Th1, although later it was found that it could induce Th1 or Th2 depending on other cytokines present (IL-12/IL-4, respectively) (29, 30) . In addition, some report that it can prime naive T cells, whereas others report effects only on memory CD4 T cells (29) (30) (31) . Some find that IL-15 can promote the formation of T regulatory cells, but that it also increases the proliferation and cytokine secretion of IFN-g-producing CD4 and CD8 T cells so that the T regulatory cells were unable to inhibit the T cells (32, 33) . In contrast, it was recently found that, in mice that lack the receptor for IL-15 signaling (IL-15Ra 2/2 ), CD4
T cells that were primed in this environment produced high levels of IL-10 (34). In view of the recent literature, we wanted to determine the effect of IL-15 on metastasis and the mechanism by which it promotes this effect. This will include whether IL- 15 
Materials and Methods

Animal models
Metastasis model
A cell line was established from a mouse mammary tumor virus/polyoma middle T (MT) C57BL/6 spontaneous breast tumor (Mayo Clinic, Scottsdale, AZ) grown in RPMI 1640 (10% FBS, 1% penicillin/streptomycin, 1% HEPES, and 1% L-glutamine). After brief trypsinization, cells were washed in PBS and resuspended as 0.5 3 10 6 -1 3 10 6 per 400 ml sterile PBS. Cells with ,5% cell death were injected via the tail vein of IL-15 2/2 , C57BL/6, or IL-15 TG mice. Mice were monitored for endpoint, and 13 d postinjection, mice were euthanized and lungs were harvested. Lungs were fixed in 2% paraformaldehyde for 48 h. Sections were then stained with H&E for analysis of lung tumor metastasis. The level of metastasis was assessed while blinded in ImageJ. In brief, in an entire lobe of lung, per each experimental animal, a threshold algorithm was applied to assess tumor area (manually checked for accuracy). Total lung area (with lumen areas subtracted) was also assessed, and percentage of tumor area was calculated by the following formula:
Percent tumor area ¼ ðtumor area=total lung areaÞ 3 100
Melanoma cells (B16F10) were also used and were prepared in the same manner as MT cells. A total of 1 3 10 5 cells was injected in the tail vein of IL-15 2/2 and C57BL/6 control mice. Lungs were harvested 14 d postinjection and fixed in paraformaldehyde, and the number of visible nodules was assessed with a stereoscope.
IL-15/IL-15Ra treatment
A dose of IL-15 (500 mg; PeproTech) and IL-15Ra (1 mg; PeproTech) in 200 ml PBS per mouse was incubated for 30 min at 37˚C prior to injection i.p. into mice. C57BL/6 mice were treated with this dose of IL-15/IL-15Ra 4 and 3 d prior to tumor cell injection, on the day of tumor cell injection and every 3-4 d till the end of the experiment. This dosing schedule had been previously tested in our laboratory (data not shown). A total of 1 3 10 6 MT cells was injected i.v. Mice were monitored for endpoint, and 13 d postinjection, mice were euthanized and lungs were harvested. Lungs were fixed in 2% paraformaldehyde for 48 h. Sections were then stained with H&E for analysis of lung tumor metastasis.
NO assay
Under anesthetic, the peritoneal cavity of the mice was washed with RPMI 1640 (10% FBS, 1% penicillin/streptomycin, 1% HEPES, and 1% L-glutamine). Resultant cells were plated for 2-4 h, and only adherent cells were collected to be used in subsequent assays. A total of 1 3 10 5 or 2 3 10 5 peritoneal macrophages was plated in 96-well plates with RPMI 1640 (10% FBS, 1% penicillin/streptomycin, 1% HEPES, and 1% L-glutamine) or media supplemented with LPS (100 ng/ml; Sigma-Aldrich). Assay was performed in triplicate. At 24 and 48 h, media was collected and combined with Greiss reagent (0.04 g/ml; Sigma-Aldrich). Absorbance was measured at 450 nm and compared with a standard curve of sodium nitrate. 
Nonspecific CD4 stimulation
Single-cell suspensions were created from spleens of IL-15 2/2 , C57BL/6, and IL-15 TG mice. CD4 T cells were isolated using CD4 T cell enrichment kit (Stem Cell) and plated at 5 3 10 5 in triplicate in 96-well plates that had been coated in purified CD3 (1 mg/ml)/CD28 (5 mg/ml) (eBioscience) Ab overnight at 4˚C (washed in 23 PBS before plating). After 48 h, the supernatant was collected and analyzed for cytokines. Control wells were included. Purity of CD4 T cells after enrichment was .85% via flow cytometry.
ELISA IL-10 (DY417) and IL-13 (DY413) ELISAs were performed using Quantikine Murine Duoset Kits from R&D Systems (Minneapolis, MN). ELISAs were performed as per manufacturer's instruction.
Isolation of cells and RNA from lungs
IL-15
2/2 mice or C57BL/6 mice were injected with 5 3 10 5 MT tumor cells i.v. Two days postinjection, lungs were perfused and harvested, and one lobe was used for RNA isolation and the other for cell isolation. For cell isolation, lungs were minced and digested in 150 U/ml collagenase I (Life Technologies) in HBSS for 1 h at 37˚C with shaking. Cells were then filtered and stained for CD16/32 (eBioscience) (1 in 100, 15 min, 4˚C), followed by staining for CD45, F480, CD11b, CD11c, GR1 or CD45, CD4, CD3 (BD Biosciences or eBioscience). CD45 + leukocytes were gated on first to begin analysis. To extract RNA, TRIzol (Invitrogen) was used initially (as per manufacturer's instruction), followed by Qiagen RNeasy Mini Kit and on-column DNase treatment (RNase-Free DNase Set 79254; Qiagen). Subsequently, 1 mg RNA per sample was used to create cDNA following the procedure outlined in RT 2 First Strand Kit 3304011; Qiagen). The cDNA was then used in a RT 2 Profiler PCR Array for Mouse Cytokines and Chemokines, as per manufacturers' instruction (RT 2 SYBR Green ROX PCR Mastermix; SABiosciences/Qiagen). This 96-well plate includes housekeeping genes, genomic DNA controls, reversetranscription controls, and positive controls. The plate was run on the Applied Biosystems 7900 RT machine. Results were analyzed using the SABiosciences analysis tool, and all samples used passed the quality controls inherent in these assays. Results are reported as fold up-or downregulation, with two samples per group included in the analysis (accession GSE61858; link to data file: http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE61858).
Statistical analysis
GraphPad Prisms was used for statistics. T tests or one-way ANOVAs were performed, depending on the number of groups to be compared. For ANOVAs, Bonferonni's posttest was employed to compare groups.
Results
IL-15
2/2 mice have increased lung metastasis, whereas IL-15 TG mice and IL-15-treated C57BL/6 mice have decreased lung metastasis in comparison with control IL-15 can impact, both directly and indirectly, many cell types that are thought to be important in the establishment of metastasis. To determine whether the absence or overexpression of IL-15 is able to affect the formation of metastasis, we used a mouse model mimicking breast tumor metastasis. IL-15
, C57BL/6, and IL-15 TG mice were injected i.v. with 5 3 10 5 MT cells (cell line established from a mouse mammary tumor virus-polyoma MT mouse breast tumor). The IL-15 2/2 mice had lungs with extensive metastasis (Fig. 1) . At the same time point, there was greatly reduced metastatic tumor burden in control mice, and metastasis was virtually absent in IL-15 TG mice (Fig. 1) , whereas they did not form in C57BL/6 mice until a dose of 5 3 10 5 . To delineate the differences between control and IL-15 TG mice, we increased the amount of tumor cells injected (1 3 10 6 ) (Fig. 2B) . In this scenario, metastasis in the control mice was much higher and was still absent in IL-15 TG mice (Fig. 2B) . Lastly, to confirm the high degree of susceptibility to MT metastasis observed in the IL-15 2/2 mice in an alternate tumor model, we injected 1 3 10 5 B16F10 melanoma cells IV (Fig. 2C) . Once again, a significantly higher degree of lung tumor formation was observed in the IL-15 2/2 mice in comparison with control C57BL/6 mice.
We also examined what would occur in our model with shortterm treatment of control C57BL/6 mice with exogenous IL-15/ IL-15Ra prior to and during the metastasis experiment. The combination of IL-15 with IL-15Ra was used for treatment, as it has been demonstrated to have higher activity, increased stabilization, and longer t 1/2 than IL-15 alone (37, 38) . We found that, at a dose of 1 3 10 6 MT cells i.v., there was extensive lung metastasis in all C57BL/6 mice, but virtually no metastasis in IL-15/ IL-15Ra-treated mice or IL-15 TG mice (Fig. 3) . Thus, shortterm administration of IL-15 was able to protect from metastasis formation.
Resistance to metastasis in IL-15 TG mice is NK cell dependent
IL-15 has very important effects on cells of both the innate and the adaptive immune system. It is known that IL-15
2/2 mice lack NK cells, whereas IL-15 TG mice have increased NK cells and CD8 T cells (35, 36, 39) . NK cells and CD8 T cells function in tumor immunosurveillance and are able to kill tumor cells (39) . To determine whether NK cells or CD8 T cells are important to the resistance observed in IL-15 TG mice, we depleted IL-15 TG mice with anti-NK1.1 or anti-CD8a Abs prior to and throughout the experiment (Fig. 4) . Depletions with these Abs were effective (data not shown). A total of 5 3 10 5 MT tumor cells was injected i.v. The depletion of NK1.1 + cells increased metastasis to levels . RNA was extracted, cDNA was synthesized, and a PCR array was performed for cytokines and chemokines (n = 2/group). Fold downregulation in IL-15 2/2 versus similar to that seen in IL-15 2/2 mice, whereas depletion of CD8
T cells had no statistically significant effect on metastasis (Fig. 4) . Therefore, NK cells are key mediators of the protection seen in IL-15 TG mice.
NK depletion in control mice increases metastasis, but not to the same level observed in IL-15 2/2 mice
To determine whether the lack of NK cells in IL-15 2/2 mice was the factor that promoted increased metastasis in these mice, control mice were depleted of NK cells before being injected with 5 3 10 5 MT cells. Depletions were maintained for the duration of the experiment. We found that, although depletion of NK cells in control mice promoted metastasis, the trend in two separate experiments was that there was still less metastasis than was observed in IL-15 2/2 mice (Fig. 5A , 5B (Fig. 6A, 6B ). Therefore, CD4
T cells in IL-15 2/2 mice promoted tumor formation. It was also found that CD4 T cells were a higher proportion of CD45 + leukocytes in the lung of IL-15 2/2 mice 2 d posttumor cell injection in comparison with control lungs (Fig. 6C) . Thus, they were a highly prevalent immune cell present in the IL-15 2/2 mouse lung microenvironment.
IL-15
2/2 mice have M2-polarized macrophages, whereas
IL-15 TG mice have M1-polarized macrophages
TAMs or M2 macrophages are an important cell type for promotion of metastasis (17, 42) . Many studies have shown that, at the primary site, TAMs promote both invasion and metastasis and are correlated with poor prognosis (11) . It has been previously found in the same model of metastasis used in this work that genetic or chemical ablation of macrophages decreases both metastatic seeding and growth (17) . To determine whether IL-15 affects the polarization of macrophages, we analyzed the ability of peritoneal macrophages from IL-15 2/2 , control, and IL-15 TG mice to produce NO in response to LPS (Fig. 7A) . IL-15 TG macrophages produced the highest amounts of NO, which indicates a M1 phenotype, whereas IL-15 2/2 mice produced the lowest amount of NO. We also examined the myeloid population present in the lungs of IL-15 2/2 and C57BL/6 mice at 2 d posttumor cell injection (Fig. 7B) . Cells in the lung were stained for F4/80 to 2 ) (43). In IL-15 2/2 mice, there was an increase in recruited macrophages brought into the lung (Fig. 7B) . Because the macrophages in IL-15 2/2 mice have an M2 polarization, it is likely that these macrophages would assist in the formation of metastasis. In prior examinations of this metastasis model, recruitment of macrophages to the site is very important for efficient metastatic seeding and growth (17, 18) .
IL-15
2/2 CD4 T cells appear to have a Th2 phenotype and may contribute to metastasis by altering macrophage polarization
To determine the phenotype of the CD4 T cells in our model, CD4 T cells were isolated from the spleen of IL-15 2/2 and control mice and stimulated nonspecifically for 48 h (Fig. 8A, 8B ). The CD4 T cells were .85% pure (data not shown). When analyzed for cytokine production, IL-15 2/2 CD4 T cells were found to produce higher levels of both IL-10 and IL-4 (Fig. 8A, 8B ). This indicated that IL-15 2/2 CD4 T cells were more Th2 skewed than control CD4
T cells. To determine whether the CD4 T cells in IL-15 2/2 mice were contributing to the M2 macrophage phenotype in these mice, peritoneal macrophages from IL-15 2/2 or CD4-depleted IL-15
mice were analyzed for their ability to produce NO. Although missing significance, in several experiments it was found that CD4 depletion restored the ability of these macrophages to make NO (Fig. 8C) . Therefore, CD4 T cells in IL-15 2/2 mice promote tumor metastasis, possibly via their effects on macrophage polarization.
Discussion
The ability of IL-15 to affect tumor formation and its effects on both NK cells and CD8 T cells have been well studied in a variety of tumor models. Unfortunately, very few studies have examined extensively the role of IL-15 in metastasis and its effects on immune cells other than NK cells or CD8 T cells. In this study, we have shown in a breast cancer model of metastasis that IL-15 overexpression or IL-15/IL-15Ra treatment greatly decreases the formation of metastatic sites in the lung, whereas lack of IL-15 highly promotes the formation of metastasis. The susceptibility of IL-15 2/2 mice to metastasis was observed in both the breast cancer MT model and a melanoma B16F10 model, thus indicating that the effect is not specific to one particular cell line or tumor type. In IL-15 TG mice, this protection was found to be dependent on NK cells. This agrees with earlier studies in which the effects of IL-15 in metastatic models of colon carcinoma or melanoma are NK cell dependent, not CD8 T cell dependent (7, 9) . We observed that the loss of IL-15, and hence NK cells, from IL-15 2/2 lungs led to a decrease in type 1 cytokines such as IFN-g, CCL5, and XCL1. These cytokines have been described as the Th1-promoting cytokines expressed by activated NK cells in certain infections (40, 41) . It is also possible that these molecules can be expressed by Th1 CD4 or CD8 T cells, as well as macrophages (40, 41, 44) . These molecules can affect many cell types to prevent the formation of lung metastasis. For example, in a model of melanoma metastasis, production of IFN-g by lung NK cells was critical for resistance to metastasis (45) . In addition, IFN-g is known to promote the formation of M1 macrophages and Th1 T cells (46 (50) . It has recently come to light that macrophages not only have a protumoral role at the primary tumor, they are also very important for the establishment of metastasis (17, 18) . They contribute both to the extravasation of the tumor cells and growth at the metastatic site (17, 18) . Therefore, we were interested in determining whether overexpression or lack of IL-15 has an impact on macrophage phenotype. The macrophages that aid in tumor formation and metastasis have multiple subtypes, but most of the functions they exhibit are more of the M2 phenotype (11, 12, 18) . Previously, there have been reports that IL-15 affects macrophages by promoting the secretion of proinflammatory cytokines and increasing MHCII (26, 28) . In this study, we found that peritoneal macrophages from IL-15 TG mice have much higher levels of NO production in comparison with wild type, whereas IL-15 2/2 macrophages produced little to no NO. NO production is typical of M1 macrophages and is a mechanism by which macrophages can cause tumor cell death (51) . Therefore, IL-15 overexpression promotes the formation of M1 macrophages, whereas lack of IL-15 changes macrophages into more of an M2 phenotype. It is unknown whether this is a direct effect of IL-15, or an effect due to how IL-15 affects other cell types. We also examined the myeloid cell environment in IL-15 2/2 and control mice 2 d posttumor cell injections. We found that IL-15 2/2 lungs had an increased proportion of recruited macrophages from the circulation. An increase in this population, not lung-resident macrophages, has been shown to aid in the extravasation and establishment of lung metastasis (17) . It has been suggested that CD4 T cells play a role in polarizing macrophages and promoting metastasis (20, 52) . Denardo et al. (20) found that, in a spontaneous mouse breast tumor model, CD4 T cells secrete Th2 cytokines that promote the formation of M2 macrophages in the primary tumor. Removal of these CD4 T cells promoted TAMs with a M1 phenotype, and, although this did not affect primary tumor growth, it did decrease the amount of metastasis (20) . In our case, we are modeling metastasis by injecting MT tumor cells i.v., so we will only observe the effects of macrophages/CD4 T cells at the metastatic site. The first step was to determine whether IL-15 was able to affect the Th1/Th2 balance of CD4 T cells. It has previously been shown that IL-15 can cause proliferation of CD4 T cells (naive and/or memory), and there are contrasting results as to whether it promotes T regulatory cells or highly active Th1 CD4 T cells (29, 30, 32) . This lack of consensus between studies is most likely due to the different in vitro and in vivo conditions under which they investigated the effect. We have shown that CD4 T cells isolated from IL-15 2/2 mice are capable of producing high levels of the Th2 cytokines IL-10 and IL-4. This indicates a more Th2 CD4 T cell in mice that lack IL-15. We have not established whether this change in CD4 T cell phenotype is directly due to loss of IL-15 or indirect due to its effects on other cells such as NK cells. As mentioned, the macrophages in IL-15 2/2 mice produce very little NO, but when we depleted CD4 T cells they produced wild-type levels of NO. Thus, the lack of IL-15 in IL-15 2/2 mice promotes CD4 T cells that are more Th2 biased and promotes the formation of M2 macrophages. It was confirmed that in vivo, CD4 depletion in IL-15 2/2 mice reduced the formation of metastasis. Therefore, CD4
T cells play an important role in promoting metastasis, and this most likely involves their impact on macrophage polarization. Further examination into whether the effects of IL-15 loss/gain on CD4 T cell and macrophage phenotype are direct or indirect would be of interest.
In this model of metastasis, IL-15 acts to decrease metastasis, whereas the absence of IL-15 promotes metastasis. These effects are due to NK cells, but also to the effects of IL-15 on other immune cells such as macrophages and CD4 T cells. Because metastasis is a significant contributor to mortality in breast cancer, this study indicates that IL-15 may be an ideal immunotherapy, and perhaps its antitumor effects on immune cells are even more widespread than previously appreciated.
